MAYO CLINIC

The PARTNER 3 trial demonstrates that transcatheter aortic valve replacement (TAVR) provides similar clinical outcomes to surgery at 7 years in low-risk patients with severe aortic stenosis.

A comprehensive analysis of 19 clinical trials involving 6,506 patients found tramadol provides only minimal pain relief that falls below clinically meaningful thresholds for chronic pain management.

Ryght AI announces formation of inaugural Scientific Advisory Board comprising 12 globally recognized experts in oncology, hematology, dermatology, and AI to guide clinical trial innovation.

Two major clinical trials presented at ASTRO 2025 reached opposite conclusions about proton beam therapy's effectiveness compared to intensity-modulated radiotherapy (IMRT) for head and neck cancer treatment.

Leo Cancer Care launched Grace™, the first upright photon therapy system, at ASTRO 2025, challenging conventional horizontal radiation therapy approaches.

Kardigan closed a $254 million Series B financing round led by Fidelity Management & Research Company and T. Rowe Price Investment Management to advance three late-stage cardiovascular programs.

Lutetium Lu 177 dotatate demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors, achieving partial responses in 17% of patients in a real-world study.

A 9-year-old golden retriever with metastatic oral melanoma achieved complete tumor remission after participating in a clinical trial testing inhaled IL-15 immunotherapy at UC Davis.

A Mayo Clinic phase 3 trial demonstrates that de-escalated adjuvant radiation therapy (DART) significantly reduces severe toxicity rates from 11% to 3% compared to standard treatment in HPV-positive oropharyngeal cancer patients.

A custom-built antisense oligonucleotide drug targeting the CHCHD10 gene mutation has slowed ALS progression by more than half in Dr. Rakesh Parekh, marking the first treatment for this specific genetic variant.